Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 1, 2009, Pages 82-89

  Carlsson, Leif ^a   Andersson, Birgit ^a   Linhardt, Gunilla ^a   Löfberg, Lena ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiarrhythmic drugs; Beat by beat QT interval variability; Ion channels; Repolarization; Torsades de pointes

Indexed keywords

AZD 1305; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL NAV1.5; DOFETILIDE; ION CHANNEL; ION CHANNEL BLOCKING AGENT; METHOXAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE VARIABILITY; HEART REPOLARIZATION; IN VIVO STUDY; ION TRANSPORT; MALE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; QT INTERVAL; RABBIT; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; INHIBITORY CONCENTRATION 50; LONG QT SYNDROME; MALE; METHOXAMINE; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; RABBITS; SULFONAMIDES; TIME FACTORS;

EID: 68349101223     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ac62c9     Document Type: Article

References (35)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J. 2006;27:1979-2030. (Pubitemid 44313588)
2. Redfern WS, Carlsson L, Davis AS, et al. Relationships between pre-clinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45. (Pubitemid 36351620)
3. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2005;2:758-772. (Pubitemid 40903686)
4. Thomsen MB, Matz J, Volders PGA, et al. Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Therapeut. 2006;112:150-170. (Pubitemid 44301487)
5. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol. 1997;30:791-798. (Pubitemid 27397663)
6. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-1652. (Pubitemid 47537839)
7. Cheng JWM. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008;42:533-542.
8. Hohnloser SH, Connolly SJ, van Eickels M, et al. Effect of dronedarone on cardiovascular outcomes: A meta-analysis of five randomized controlled trials in 6157 patients with atrial fibrillation/flutter. J Am Coll Cardiol. 2009;53:A113.
9. Wu Y, Carlsson L, Liu T, et al. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol. 2005; 16:898-904. (Pubitemid 41623783)
10. Carlsson L. The anesthetized methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol Therapeutics. 2008;119:160-167.
11. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation. 2004;10,2453-2459. (Pubitemid 39407353)
12. Persson F, Carlsson L, Duker G, et al. Blocking characteristics of hERG, hNav1.5 and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol. 2005;16: 329-341. (Pubitemid 40404601)
13. Persson F, Carlsson L, Duker G, et al. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol. 2005;46:7-17. (Pubitemid 40917773)
14. Persson F, Andersson B, Duker G, et al. Functional effects of the late sodium current blockade by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol. 2007; 558:133-143. (Pubitemid 46350691)
15. Crijns HJ, Van Gelder IC, Walfridsson A, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006;3:1321-1331.
16. Geller JC, Egstrup K, Kulakowski P, et al. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol. 2009;49:312-322.
17. Amos GJ, Abrahamsson C, Duker G, et al. Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52 - Implications for proarrhythmic potential. Cardiovasc Res. 2001;49: 351-360. (Pubitemid 32119552)
18. Na and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006;70:486-496.
19. Carlsson L, Drews L, Duker G, et al. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther. 1993;267:1076-1080. (Pubitemid 24068667)
20. ++ overload. J Pharmacol Exp Ther. 1996;279:231-239.
21. Hondeghem L, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013. (Pubitemid 32322230)
22. Hinterseer M, Thomsen MB, Beckmann B, et al. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. Eur Heart J. 2008;29:85-190.
23. Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J. 2008;15:100-121.
24. Svernhage E, Houltz B, Blomström P, et al. Early electrocardiographic signs of drug-induced torsades de pointes. Ann Noninvasive Electrophysiol. 1998;3:252-260. (Pubitemid 28364442)
25. Wang D, Patel C, Cui C, et al. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Therapeutics. 2008;119:141-151.
26. Antzelevitch C, Sicouri S, Di Diego JM, et al. Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm. 2007; 4:1114-1116.
27. Topilski I, Rogowski O, Rosse R, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. JACC. 2007;49:320-328. (Pubitemid 46110956)
28. Vincze D, Farkas AS, Rudas L, et al. Relevance of anaesthesia for dofetilide-induced torsades de pointes in a-adrenoceptor-stimulated rabbits. Br J Pharmacol. 2008;153:75-89.
29. Darbar D, Kimbrough J, Jawaid A, et al. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol. 2008;51:836-842. (Pubitemid 351253747)
30. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current." Pharmacol Ther. 2008:326-339.
31. Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192-199. (Pubitemid 38982162)
32. Wang WQ, Robertson C, Dhalla AK, et al. Antitorsadogenic effects of (±)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl] -1-piperazine (Ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008;325:875-881.
33. Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. J Pharmacol Exp Ther. 1996;276:637-646. (Pubitemid 126660502)
34. Huang Z, Dai D, Li N, et al. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. Clin Exp Pharmacol Physiol. 2007;34:310-317. (Pubitemid 46257049)
35. Abrahamsson C, Carlsson L, Duker G. Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarisation and early after depolarisations in vitro. J Cardiovasc Electrophysiol. 1996;7:1074-1081. (Pubitemid 26389421)